» Articles » PMID: 28210785

On Glioblastoma and the Search for a Cure: Where Do We Stand?

Overview
Publisher Springer
Specialty Biology
Date 2017 Feb 18
PMID 28210785
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Although brain tumours have been documented and recorded since the nineteenth century, 2016 marked 90 years since Percival Bailey and Harvey Cushing coined the term "glioblastoma multiforme". Since that time, although extensive developments in diagnosis and treatment have been made, relatively little improvement on prognosis has been achieved. The resilience of GBM thus makes treating this tumour one of the biggest challenges currently faced by neuro-oncology. Aggressive and robust development, coupled with difficulties of complete resection, drug delivery and therapeutic resistance to treatment are some of the main issues that this nemesis presents today. Current treatments are far from satisfactory with poor prognosis, and focus on palliative management rather than curative intervention. However, therapeutic research leading to developments in novel treatment stratagems show promise in combating this disease. Here we present a review on GBM, looking at the history and advances which have shaped neurosurgery over the last century that cumulate to the present day management of GBM, while also exploring future perspectives in treatment options that could lead to new treatments on the road to a cure.

Citing Articles

Assessing Glioblastoma Treatment Response Using Machine Learning Approach Based on Magnetic Resonance Images Radiomics: An Exploratory Study.

Sadeghinasab A, Fatahiasl J, Tahmasbi M, Razmjoo S, Yousefipour M Health Sci Rep. 2025; 8(1):e70323.

PMID: 39741746 PMC: 11683675. DOI: 10.1002/hsr2.70323.


Ursolic acid inhibits glioblastoma through suppressing TGFβ-mediated epithelial-mesenchymal transition (EMT) and angiogenesis.

Hei B, Liu R, Li M Heliyon. 2024; 10(6):e27722.

PMID: 38501006 PMC: 10945258. DOI: 10.1016/j.heliyon.2024.e27722.


MiR-128-3p - a gray eminence of the human central nervous system.

Kiel K, Krol S, Bronisz A, Godlewski J Mol Ther Nucleic Acids. 2024; 35(1):102141.

PMID: 38419943 PMC: 10899074. DOI: 10.1016/j.omtn.2024.102141.


Endosome associated trafficking regulator 1 promotes tumor growth and invasion of glioblastoma multiforme via inhibiting TNF signaling pathway.

Zhang Q, Dai Z, Chen Y, Li Q, Guo Y, Zhu Z J Neurooncol. 2024; 166(1):113-127.

PMID: 38191954 DOI: 10.1007/s11060-023-04527-9.


Chimeric Antigen Receptor T Cells in Glioblastoma-Current Concepts and Promising Future.

Kringel R, Lamszus K, Mohme M Cells. 2023; 12(13).

PMID: 37443804 PMC: 10340625. DOI: 10.3390/cells12131770.


References
1.
Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

2.
Bastiancich C, Vanvarenberg K, Ucakar B, Pitorre M, Bastiat G, Lagarce F . Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma. J Control Release. 2016; 225:283-93. DOI: 10.1016/j.jconrel.2016.01.054. View

3.
Liu G, Franssen E, Fitch M, Warner E . Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997; 15(1):110-5. DOI: 10.1200/JCO.1997.15.1.110. View

4.
Rouleau M, Patel A, Hendzel M, Kaufmann S, Poirier G . PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010; 10(4):293-301. PMC: 2910902. DOI: 10.1038/nrc2812. View

5.
Ramirez Y, Mladek A, Phillips R, Gynther M, Rautio J, Ross A . Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth. Mol Cancer Ther. 2014; 14(1):111-9. PMC: 4297195. DOI: 10.1158/1535-7163.MCT-14-0113. View